Literature DB >> 21187520

Clinical significance of vimentin-positive gastric cancer cells.

Yuhiko Fuyuhiro1, Masakazu Yashiro, Satoru Noda, Shinichiro Kashiwagi, Junko Matsuoka, Yosuke Doi, Yukihiro Kato, Naoshi Kubo, Masaichi Ohira, Kosei Hirakawa.   

Abstract

BACKGROUND/AIM: Vimentin expression in epithelial cells is reported to be associated with the malignant phenotype of cancer cells in vitro. However, the clinical significance of vimentin expression in carcinomas is not well understood. The aim of this study was to clarify the significance of vimentin-positive gastric cancer (GC). PATIENTS AND METHODS: A total of 265 GCs were examined by immunofluorescent staining with antibodies against vimentin and carcinoembryonic antigen. GCs were determined to be vimentin-positive when cells were positive for both vimentin and carcinoembryonic antigen staining.
RESULTS: A total of 86 (32%) of 265 GCs were vimentin positive. There was a statistically significant correlation between vimentin-positive GCs and advanced clinical stage (p<0.001), macroscopic scirrhous-type (p < 0.001), histological diffuse-type (p < 0.001), lymph node metastasis (p = 0.008) and lymphatic invasion (p = 0.013). The prognosis of patients with vimentin-positive GCs was significantly (p < 0.001) worse than that with vimentin-negative GCs.
CONCLUSION: Vimentin expression might contribute to the high invasive phenotype of GC, and may be a useful biomarker to determine the biological aggressiveness of GC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187520

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

Review 1.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

2.  DNA-aptamer targeting vimentin for tumor therapy in vivo.

Authors:  Tatyana N Zamay; Olga S Kolovskaya; Yury E Glazyrin; Galina S Zamay; Svetlana A Kuznetsova; Ekaterina A Spivak; Mohamed Wehbe; Anna G Savitskaya; Olga A Zubkova; Anastasia Kadkina; Xiaoyan Wang; Darija Muharemagic; Anna Dubynina; Yuliya Sheina; Alla B Salmina; Maxim V Berezovski; Anna S Zamay
Journal:  Nucleic Acid Ther       Date:  2014-01-11       Impact factor: 5.486

3.  Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis.

Authors:  Green Kim; Tae-Hyoun Kim; Eun-Ha Hwang; Kyu-Tae Chang; Jung Joo Hong; Jong-Hwan Park
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

4.  Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients.

Authors:  Futao Hou; Weijie Yuan; Jin Huang; Liyuan Qian; Zhikang Chen; Jie Ge; Shaobin Wu; Jinxiang Chen; Jixu Wang; Zihua Chen
Journal:  Med Oncol       Date:  2011-12-22       Impact factor: 3.064

5.  TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals.

Authors:  Jian Bai; Shuyuan Yeh; Xiaofu Qiu; Linyi Hu; Jun Zeng; Yangke Cai; Li Zuo; Gonghui Li; Guosheng Yang; Chawnshang Chang
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

6.  Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.

Authors:  Hongyu Wang; Xin Li; David E Volk; Ganesh L-R Lokesh; Miguel-Angel Elizondo-Riojas; Li Li; Alpa M Nick; Anil K Sood; Kevin P Rosenblatt; David G Gorenstein
Journal:  Biotechniques       Date:  2016-11-01       Impact factor: 1.993

7.  Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.

Authors:  Zahra Daman; Hamed Montazeri; Masoumeh Azizi; Faegheh Rezaie; Seyed Nasser Ostad; Mohsen Amini; Kambiz Gilani
Journal:  Pharm Res       Date:  2015-07-31       Impact factor: 4.200

8.  URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro.

Authors:  Xiaoxia Hu; Fei Zhang; Dongwei Luo; Na Li; Qian Wang; Zhonghai Xu; Huiqin Bian; Yuting Liang; Yaojuan Lu; Qiping Zheng; Junxia Gu
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

9.  Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp.

Authors:  Shogo Kawaguchi; Tetsuro Yoshimura; Hirotake Sakuraba; Taka Asari; Yohei Sawada; Yasumitsu Araki; Koji Kikuchi; Toyohito Wada; Tomomi Kusumi; Shinsaku Fukuda
Journal:  Clin J Gastroenterol       Date:  2018-02-07

Review 10.  The aberrant overexpression of vimentin is linked to a more aggressive status in tumours of the gastrointestinal tract.

Authors:  Marlena Brzozowa; Grzegorz Wyrobiec; Izabela Kołodziej; Mateusz Sitarski; Natalia Matysiak; Edyta Reichman-Warmusz; Małgorzata Żaba; Romuald Wojnicz
Journal:  Prz Gastroenterol       Date:  2015-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.